Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma

被引:26
作者
Lipton, L
Fleischmann, C
Sieber, OA
Thomas, HJW
Hodgson, SV
Tomlinson, IPM
Houlston, RS
机构
[1] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England
[2] London Res Inst, Mol & Populat Genet Lab, Canc Res UK, London WC2A 3PX, England
[3] St Marks Hosp, Canc Res UK Colorectal Unit, Harrow HA1 3UJ, Middx, England
[4] Guys Hosp, Dept Clin Genet, London SE1 9RT, England
关键词
CHEK2; 1100deIC; colorectal; neoplasm;
D O I
10.1016/S0304-3835(03)00391-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aneuploidy is a characteristic of a subset of colorectal tumours. CHEK2 (also known as CHK2) is one of the cell cycle checkpoint genes coding for a family of proteins that sense damage in eukaryotic cells. Germline variation in CHEK2 has recently been shown to confer cancer susceptibility. Heterozygous mutations have been identified in patients with TP53-negative Li-Fraumeni syndrome. Furthermore, the CHEK2 1100delC variant carried by 1% of the population has been shown to act as a low penetrance allele for both breast and prostate cancers. To further our knowledge about the contribution of CHEK2 1100delC to cancer incidence we have analysed a series of 149 patients with multiple colorectal adenomas some of whom developed colorectal cancer. The CHEK2 1100delC allele was not over-represented in cases suggesting that this variant is not associated with an increased risk of colorectal disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 152
页数:4
相关论文
共 16 条
  • [1] Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
    Bell, DW
    Varley, JM
    Szydlo, TE
    Kang, DH
    Wahrer, DCR
    Shannon, KE
    Lubratovich, M
    Verselis, SJ
    Isselbacher, KJ
    Fraumeni, JF
    Birch, JM
    Li, FP
    Garber, JE
    Haber, DA
    [J]. SCIENCE, 1999, 286 (5449) : 2528 - 2531
  • [2] BONAITIPELLIE C, 1989, EUR J CANCER PREV, V8, pS27
  • [3] BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655
  • [4] Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
    Chaturvedi, P
    Eng, WK
    Zhu, Y
    Mattern, MR
    Mishra, R
    Hurle, MR
    Zhang, XL
    Annan, RS
    Lu, Q
    Faucette, LF
    Scott, GF
    Li, XT
    Carr, SA
    Johnson, RK
    Winkler, JD
    Zhou, BBS
    [J]. ONCOGENE, 1999, 18 (28) : 4047 - 4054
  • [5] CHEHAB HN, 2000, GENE DEV, V14, P289
  • [6] Mutations in CHEK2 associated with prostate cancer risk
    Dong, XY
    Wang, L
    Taniguchi, K
    Wang, XS
    Cunningham, JM
    McDonnell, SK
    Qian, CP
    Marks, AF
    Slager, SL
    Peterson, BJ
    Smith, BI
    Cheville, JC
    Blute, ML
    Jacobsen, SJ
    Schaid, DJ
    Tindall, DJ
    Thibodeau, SN
    Liu, WG
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (02) : 270 - 280
  • [7] A SIMPLE APPROXIMATION FOR CALCULATING SAMPLE SIZES FOR COMPARING INDEPENDENT PROPORTIONS
    FLEISS, JL
    TYTUN, A
    URY, HK
    [J]. BIOMETRICS, 1980, 36 (02) : 343 - 346
  • [8] Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
    Ingvarsson, S
    Sigbjornsdottir, BI
    Chen, HP
    Hafsteinsdottir, SH
    Ragnarsson, G
    Barkardottir, RB
    Arason, A
    Egilsson, V
    Bergthorsson, JT
    [J]. BREAST CANCER RESEARCH, 2002, 4 (03)
  • [9] Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
    Laken, SJ
    Petersen, GM
    Gruber, SB
    Oddoux, C
    Ostrer, H
    Giardiello, FM
    Hamilton, SR
    Hampel, H
    Markowitz, A
    Klimstra, D
    Jhanwar, S
    Winawer, S
    Offit, K
    Luce, MC
    Kinzler, KW
    Vogelstein, B
    [J]. NATURE GENETICS, 1997, 17 (01) : 79 - 83
  • [10] hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
    Lee, JS
    Collins, KM
    Brown, AL
    Lee, CH
    Chung, JH
    [J]. NATURE, 2000, 404 (6774) : 201 - 204